TERT promoter mutations in atypical melanocytic lesions: A series of seven cases with adverse melanoma-specific outcome

Reed Huber,Jonathan Lee,Lisa Borretta,Basile Tessier-Cloutier,Amy Lum,Stephen Yip,Basil A. Horst
DOI: https://doi.org/10.1016/j.humpath.2024.01.003
IF: 3.526
2024-01-15
Human Pathology
Abstract:The majority of melanocytic proliferations can be readily categorized as benign or malignant based on histologic assessment under the microscope by a trained dermatopathologist. However, a subset of lesions, termed Atypical Melanocytic Proliferations (AMPs), are histologically ambiguous, leading to possible diagnostic error and suboptimal treatment. Mutations in the promoter region of the catalytic subunit of telomerase, telomerase reverse transcriptase (TERT), are commonly found in melanomas but are rare in melanocytic nevi. In this study, we aimed to determine the prevalence of hot spot TERT promoter ( TERT -p) mutations in AMPs with adverse melanoma-specific outcome. Studies were approved by respective institutional review boards. Using a multi-center database, we identified seven cases of melanocytic proliferations with a clinical follow-up period of at least 4 years, which were initially diagnosed as AMPs, and which recurred either as melanoma at site of prior biopsy or as metastatic melanoma. Sequencing of the TERT -p region showed hotspot mutations in three cases (43 %), suggesting that TERT -p mutations are enriched and could aid in the identification of AMPs with adverse outcome. In comparison with existing ancillary techniques for prognostication of AMPs, TERT -p mutation analysis may have advantages in terms of cost effectiveness and turnaround time, and is a promising diagnostic parameter with potential widespread utility.
pathology
What problem does this paper attempt to address?